Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence

References

• World Health Organization. WHO position paper on hepatitis A vaccines – June 2012. Wkly Epid Rec. 2012;87:261–76.
   PubMedGoogle Scholar
• Rein DB, Stevens G, Flaxman A, Wittenborn JS, Timothy N, Wiktor SZ, Wiersma ST. P703 THE GLOBAL BURDEN OF HEPATITIS A VIRUS IN 1990 AND 2005. J Hepatol. 2014;60(1):S303. doi:10.1016/S0168-8278(14)60865-5.
   Web of Science ®Google Scholar
• World Health Organization, Shouval D, Van Damme P. WHO immunological basis for immunization series: module 18: hepatitis A (update 2019)2019; [ accessed 2020 Mar 12]. https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2018;68(1):167–84. doi:10.1016/j.jhep.2017.08.034.
   Web of Science ®Google Scholar
• Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109(5):839–45. doi:10.1542/peds.109.5.839.
   PubMed Web of Science ®Google Scholar
• Chen C-M, Chen SCC, Yang H-Y, Yang S-T, Wang C-M. Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study. J Viral Hepat. 2016;23(11):940–45. doi:10.1111/jvh.12564.
   PubMed Web of Science ®Google Scholar
• Vaughan G, Goncalves Rossi LM, Forbi JC, de-Paula VS, Purdy MA, Xia G, Khudyakov YE. Hepatitis A virus: host interactions, molecular epidemiology and evolution. Infect Genet Evol. 2014;21:227–43. doi:10.1016/j.meegid.2013.10.023.
   PubMed Web of Science ®Google Scholar
• Long D, Fix OK, Deng X, Seielstad M, Lauring AS. Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis A virus infection. J Med Virol. 2014;86(10):1661–68. doi:10.1002/jmv.24007.
   PubMed Web of Science ®Google Scholar
• Mayorga Perez O, Brinkhof MWG, Egger M, Frösner G, Herzog C, Zwahlen M. Decreasing risk of hepatitis A infection in León, Nicaragua: evidence from cross-sectional and longitudinal seroepidemiology studies. PLoS ONE. 2014;9(2):e87643. doi:10.1371/journal.pone.0087643.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR–7):1–23.
   PubMedGoogle Scholar
• Walker CM. Adaptive immune responses in hepatitis A virus and hepatitis E virus infections. Cold Spring Harb Perspect Med. 2019;9(9):a033472. doi:10.1101/cshperspect.a033472.
   PubMed Web of Science ®Google Scholar
• Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol. 2012;4:68–73.
   PubMedGoogle Scholar
• Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol. 2005;34(3):600–09. doi:10.1093/ije/dyi062.
   PubMed Web of Science ®Google Scholar
• GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. The Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2.
   PubMed Web of Science ®Google Scholar
• Brinkhof MWG, Mayorga O, Bock J, Heininger U, Herzog C. Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine. 2013;31(11):1490–95. doi:10.1016/j.vaccine.2013.01.011.
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–57. doi:10.1016/j.vaccine.2010.08.037.
   PubMed Web of Science ®Google Scholar
• Jacobsen K. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. 2009. [accessed 2020 Mar 12] http://apps.who.int/iris/bitstream/handle/10665/70180/WHO_IVB_10.01_eng.pdf;jsessionid=E90CC2AAACC8621E9AD4518215D72976?sequence=.
   Google Scholar
• Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004;132(6):1005–22. doi:10.1017/S0950268804002857.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics. 2009;124(6):1633–41. doi:10.1542/peds.2008-3645.
   PubMed Web of Science ®Google Scholar
• Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W. Development, production, and postmarketing surveillance of hepatitis A vaccines in China. J Epidemiol. 2014;24(3):169–77. doi:10.2188/jea.JE20130022.
   PubMed Web of Science ®Google Scholar
• Xu Z-Y, Wang X-Y. Live attenuated hepatitis A vaccines developed in China. Hum Vaccin Immunother. 2014;10(3):659–66. doi:10.4161/hv.27124.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang F, Zheng H, Miao N, Yuan Q, Cui F, Yin Z, Zhang G, Levine H. The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004–2016. Vaccine. 2018;36(10):1279–84. doi:10.1016/j.vaccine.2018.01.043.
   PubMed Web of Science ®Google Scholar
• Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G. A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother. 2016;12:3160–65.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis. 2013;56(10):1458–65. doi:10.1093/cid/cit048.
   PubMed Web of Science ®Google Scholar
• Shouval D, Ashur Y, Adler R, Lewis JA, Armstrong ME, Davide JP, McGuire B, Kuter B, Brown L, Miller W, et al. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine. 1993;11(Suppl 1):S9–14. doi:10.1016/0264-410X(93)90151-M.
   PubMedGoogle Scholar
• Askling HH, Rombo L, van Vollenhoven R, Hallén I, Å T, Nordin M, Herzog C, Kantele A. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014;12(2):134–42. doi:10.1016/j.tmaid.2014.01.005.
   PubMed Web of Science ®Google Scholar
• Melgaço JG, Morgado LN, Santiago MA, deOliveira JM, Lewis-Ximenez LL, Hasselmann B,  Gonçalves Cruz O, Alves Pinto M, Lamarca Vitril C. A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection. Vaccine. 2015;33:3813–20.
   PubMed Web of Science ®Google Scholar
• D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med. 2006;13(2):78–83. doi:10.1111/j.1708-8305.2006.00001.x.
   PubMed Web of Science ®Google Scholar
• Genton B, D’Acremont V, Furrer H-J, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel Med Infect Dis. 2006;4(6):303–12. doi:10.1016/j.tmaid.2005.10.002.
   PubMedGoogle Scholar
• Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32:e00084–18.
   PubMed Web of Science ®Google Scholar
• Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C. Single-dose hepatitis A immunization: 7.5-year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response. J Infect Dis. 2016;214(10):1498–506.
   PubMed Web of Science ®Google Scholar
• Fritzsche C, Loebermann M, Reisinger EC. A case of acute hepatitis A infection in an HIV-positive patient despite complete hepatitis A vaccination. Infection. 2018;46(4):565–67. doi:10.1007/s15010-018-1129-1.
   PubMed Web of Science ®Google Scholar
• Vestergaard HT, Harritshøj LH, Midgley SE, Ullum H, Kampmann P. Transfusion transmission of hepatitis A virus with fecal shedding in a previously hepatitis A vaccinated recipient. J Infect Chemother. 2018;24(9):766–68. doi:10.1016/j.jiac.2018.01.020.
   PubMed Web of Science ®Google Scholar
• Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med. 1992;327(7):453–57. doi:10.1056/NEJM199208133270702.
   PubMed Web of Science ®Google Scholar
• Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntyakorn S, Suknuntapong T, Safary A, Tang DB, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271(17):1328–34. doi:10.1001/jama.1994.03510410040030.
   PubMed Web of Science ®Google Scholar
• Mayorga Pérez O, Herzog C, Zellmeyer M, Loáisiga A, Frösner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis. 2003;188(5):671–77. doi:10.1086/377309.
   PubMed Web of Science ®Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294(2):202–10. doi:10.1001/jama.294.2.202.
   PubMed Web of Science ®Google Scholar
• Zhao YL. H2 strain attenuated live hepatitis A vaccines: protective efficacy in a hepatitis A outbreak. World J Gastroenterol. 2000;6(6):829. doi:10.3748/wjg.v6.i6.829.
   Google Scholar
• Ma F, Yang J, Kang G, Sun Q, Lu P, Zhao Y, Wang Z, Luo J, Wang Z. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study. Clin Microbiol Infect. 2016;22(9):811.e9–811.e15. doi:10.1016/j.cmi.2016.06.004.
   PubMed Web of Science ®Google Scholar
• Wang X, Pan Y, Chen J, Luo J, Xi J, Ye C, Zhao Y, Qiu L, Weng S, Hong S, et al. The excretion rate and stability of HAAg in human fecal samples after live attenuated hepatitis A vaccination. J Med Virol. 2020; Online ahead of print. doi:10.1002/jmv.25747.
   Web of Science ®Google Scholar
• Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A Systematic Review Vaccine. 2012;31:3–11.
   PubMed Web of Science ®Google Scholar
• Bian G-L, Ma R, Dong H-J, Ni H-X, Hu F-J, Chen Y-R, Chen JQ, Zhou SY, Lin YX, Xu GZ. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010;28(30):4798–801.
   PubMed Web of Science ®Google Scholar
• Espul C, Cuello H, Lo Castro I, Bravo C, Thollot Y, Voznica J, Vigne C, Coudeville L. Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina. Vaccine. 2020;38(7):1715–22. doi:10.1016/j.vaccine.2019.12.049.
   PubMed Web of Science ®Google Scholar
• López EL, Contrini MM, Mistchenko A, Kieffer A, Baggaley RF, Di Tanna GL, Desai K, Rasuli A, Armoni J. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children. Pediatr Infect Dis J. 2015;34(4):417–25. doi:10.1097/INF.0000000000000605.
   PubMed Web of Science ®Google Scholar
• Plumb ID, Bulkow LR, Bruce MG, Hennessy TW, Morris J, Rudolph K, Spradling P, Snowball M, McMahon BJ. Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska. J Viral Hepat. 2017;24(7):608–12. doi:10.1111/jvh.12676.
   PubMed Web of Science ®Google Scholar
• Mosites E, Gounder P, Snowball M, Morris J, Spradling P, Nelson N, Bulkow L, Bruce M, McMahon B. Hepatitis A vaccine immune response 22 years after vaccination. J Med Virol. 2018;90(8):1418–22. doi:10.1002/jmv.25197.
   PubMed Web of Science ®Google Scholar
• Raczniak GA, Thomas TK, Bulkow LR, Negus SE, Zanis CL, Bruce MG, Spradling PR, Teshale EH, McMahon BJ. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine. 2013;31(17):2152–55. doi:10.1016/j.vaccine.2013.02.048.
   PubMed Web of Science ®Google Scholar
• Sharapov UM, Bulkow LR, Negus SE, Spradling PR, Homan C, Drobeniuc J, Bruce M, Kamili S, Hu DJ, McMahon BJ, et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology. 2012;56(2):516–22. doi:10.1002/hep.25687.
   PubMed Web of Science ®Google Scholar
• Sintusek P, Sa-nguanmoo P, Posuwan N, Jaroonvanichkul V, Vorayingyong A, Poovorawan Y. Changes in hepatitis A virus (HAV) seroprevalence in medical students in Bangkok, Thailand, from 1981 to 2016. BMC Res Notes. 2018;11(1):379. doi:10.1186/s13104-018-3733-7.
   PubMedGoogle Scholar
• Spradling PR, Bulkow LR, Negus SE, Homan C, Bruce MG, McMahon BJ. Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up. Hepatology. 2016;63:703–11.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Kafeja F, Van der Wielen M, Leyssen M, Jacquet J-M. Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age. Pediatr Infect Dis J. 2011;30(8):703–05. doi:10.1097/INF.0b013e3182138296.
   PubMed Web of Science ®Google Scholar
• Wang Y, Qi Y, Xu W, Hu Y, Wang L, Yu Y, Jiang Z, Xia J, Zeng G, Wang Y, et al. Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. Hum Vaccin Immunother. Online ahead of print, 2020;1–6. doi:10.1080/21645515.2020.1715687.
   PubMed Web of Science ®Google Scholar
• Mosites E, Seeman S, Negus S, Homan C, Morris J, Nelson NP, Spradling PR, Bruce M, McMahon B. Immunogenicity of the hepatitis A vaccine 20 years after infant immunization. Vaccine. 2020;38(32):4940–43. doi:10.1016/j.vaccine.2020.05.069.
   PubMed Web of Science ®Google Scholar
• Beran J, Van der Meeren O, Leyssen M, D’silva P. Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine. 2016;34(24):2686–91. doi:10.1016/j.vaccine.2016.04.033.
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine. 2008;26(14):1759–63. doi:10.1016/j.vaccine.2008.01.014.
   PubMed Web of Science ®Google Scholar
• Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, Stals C. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine. 2017;35(10):1448–54. doi:10.1016/j.vaccine.2017.01.031.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, Bell B, McMahon B. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198(12):1776–82. doi:10.1086/593335.
   PubMedGoogle Scholar
• Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007;25:927–31.
   PubMed Web of Science ®Google Scholar
• Theeten H, Van Herck K, Van der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 2015;33(42):5723–27. doi:10.1016/j.vaccine.2015.07.008.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van der Meeren O. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccin Immunother. 2017;13(5):972–80. doi:10.1080/21645515.2016.1274473.
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, Loutan L. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol. 2010;82(10):1629–34. doi:10.1002/jmv.21883.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, Shouval D, Bonanni P, Connor B, Cooksley G, et al. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362(9389):1065–71. doi:10.1016/S0140-6736(03)14418-2.
   PubMed Web of Science ®Google Scholar
• Burgess MA, McIntyre PB, Hellard M, Ruff TA, Lefevre I, Bock HL. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28(10):2222–26. doi:10.1016/j.vaccine.2009.12.053.
   PubMed Web of Science ®Google Scholar
• Chan CY, Lee SD, Yu MI, Wang YJ, Chang FY, Lo KJ. Long-term follow-up of hepatitis A vaccination in children. Vaccine. 1999;17(4):369–72. doi:10.1016/S0264-410X(98)00200-X.
   PubMed Web of Science ®Google Scholar
• Fan PC, Chang MH, Lee PI, Safary A, Lee CY. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine. 1998;16(2–3):232–35. doi:10.1016/S0264-410X(97)00179-5.
   PubMed Web of Science ®Google Scholar
• Mayorga O, Bock J, Egger M, Frösner G, Ibanez R, Herzog C. Long-term immunogenicity of a virosomal, aluminium-free hepatitis A vaccine in Nicaraguan children. Poster presented at: 43th ICAAC; 2003 Sept 14–17; Chicago.
   Google Scholar
• Van Herck K, Hens A, de Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine. Pediatr Infect Dis J. 2015;34(4):e85–91.
   PubMed Web of Science ®Google Scholar
• Dagan R, Ashkenazi S, Livni G, Go O, Bagchi P, Sarnecki M. Long-term Serologic follow-up of children vaccinated with a pediatric formulation of virosomal hepatitis A vaccine administered with routine childhood vaccines at 12–15 months of age. Pediatr Infect Dis J. 2016;35(7):e220–8. doi:10.1097/INF.0000000000001176.
   PubMed Web of Science ®Google Scholar
• Gilca V, Dionne M, Boulianne N, Murphy D, de Serres G. Long-term immunogenicity of two pediatric doses of combined hepatitis A and B or monovalent hepatitis B vaccine in 8 to 10-year-old children and the effect of a challenge dose given seven years later. Pediatr Infect Dis J. 2009;28:916–18.
   PubMed Web of Science ®Google Scholar
• Yu C, Song Y, Qi Y, Li C, Jiang Z, Li C, Zhang W, Wang L, Xia J. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study. Hum Vaccin Immunother. 2016;12(10):2595–602. doi:10.1080/21645515.2016.1197450.
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Livni G, Greenberg D, Abu-Abed J, Guy L, Ashkenazi S, Froesner G, Tewald F, Schaetzl HM, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(9):787–93. doi:10.1097/INF.0b013e318060acbd.
   PubMed Web of Science ®Google Scholar
• Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, Byrd KK, Sharapov UM, Hennessy TW, McMahon BJ, et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis. 2013;207(3):493–96. doi:10.1093/infdis/jis710.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis. 2013;17(11):e939–44. doi:10.1016/j.ijid.2013.04.012.
   PubMed Web of Science ®Google Scholar
• Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine. 2000;19(4–5):399–402. doi:10.1016/S0264-410X(00)00188-2.
   PubMed Web of Science ®Google Scholar
• Beck BR, Hatz C, Brönnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin Infect Dis. 2003;37(9):e126–8. doi:10.1086/378890.
   PubMed Web of Science ®Google Scholar
• Iwarson S, Lindh M, Widerström L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med. 2004;11(2):120–21. doi:10.2310/7060.2004.17079.
   PubMed Web of Science ®Google Scholar
• Vizzotti C, González J, Gentile A, Rearte A, Ramonet M, Cañero-Velasco MC, Pérez Carrega ME, Urueña A, Diosque M. Impact of the single-dose immunization strategy against hepatitis A in Argentina. Pediatr Infect Dis J. 2014;33(1):84–88. doi:10.1097/INF.0000000000000042.
   PubMed Web of Science ®Google Scholar
• Urueña A, González JE, Rearte A, Pérez Carrega ME, Calli R, Pagani MF, Uboldi A, Vicentín R, Caglio P, Cañero-Velasco MC, et al. Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination. Pediatr Infect Dis J. 2016;35(12):1339–42. doi:10.1097/INF.0000000000001322.
   PubMed Web of Science ®Google Scholar
• Vizzotti C, González J, Rearte A, Urueña A, Pérez Carrega M, Calli R, Gentile A, Uboldi A, Ramonet M, Canero-Velasco M, et al. Single-dose universal hepatitis A immunization in Argentina: low viral circulation and high persistence of protective antibodies up to 4 years. J Pediatric Infect Dis Soc. 2015;4(4):e62–7. doi:10.1093/jpids/piu068.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhu X, Hu Y, Liang M, Sun J, Song Y, Yang Q, Ji H, Zeng G, Song L, et al. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother. 2017;13(6):1314–19. doi:10.1080/21645515.2016.1278329.
   PubMed Web of Science ®Google Scholar
• Espul C, Benedetti L, Linares M, Cuello H, Lo Castro I, Thollot Y, Rasuli A. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. Hum Vaccin Immunother. 2017;13(11):2707–12. doi:10.1080/21645515.2017.1358326.
   PubMed Web of Science ®Google Scholar
• Bhave S, Sapru A, Bavdekar A, Kapatkar V, Mane A. Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children. Indian Pediatr. 2015;52(8):687–90. doi:10.1007/s13312-015-0697-8.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhou C-L, Zhang X-J, Hao Z-Y, Zhang Y-H, Wang S-M, Ma J-C, Zhao G, Qiu C, Zhao Y-L, et al. Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine. Vaccine. 2018;36(1):114–21. doi:10.1016/j.vaccine.2017.11.036.
   PubMed Web of Science ®Google Scholar
• Mitra M, Shah N, Faridi M, Ghosh A, Sankaranarayanan VS, Aggarwal A, Chatterjee S, Bhattacharyya N, Kadhe G, Vishnoi G, et al. Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis A vaccine in children. Hum Vaccin Immunother. 2015;11(5):1147–52. doi:10.4161/21645515.2014.979646.
   PubMed Web of Science ®Google Scholar
• Wang X-Y, Xu Z-Y, Ma J-C, von Seidlein L, Zhang Y, Hao Z-Y, Han OP, Zhang YL, Tian MY, Ouyang PY, et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine. 2007;25(3):446–49.
   PubMed Web of Science ®Google Scholar
• Zhuang F-C, Qian W, Mao Z-A, Gong Y-P, Jiang Q, Jiang L-M,Chen NL, Chai SA, Mao JS. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chin Med J. 2005;118(22):1851–56.
   PubMed Web of Science ®Google Scholar
• Zhuang F-C, Mao Z-A, Jiang L-M, Wu J, Chen Y-Q, Jiang Q,Chen NL, Chai SA, Mao JS. Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain) - a study on the result of 15 years’ follow up. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31(12):1332–35.
   PubMedGoogle Scholar
• Andraud M, Lejeune O, Musoro JZ, Ogunjimi B, Beutels P, Hens N. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis A virus. PLoS Comput Biol. 2012;8(3):e1002418. doi:10.1371/journal.pcbi.1002418.
   PubMed Web of Science ®Google Scholar
• Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, Shapiro CN, McMahon BJ. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J. 2007;26(2):116–22. doi:10.1097/01.inf.0000253253.85640.cc.
   PubMed Web of Science ®Google Scholar
• Hatz C, van der Ploeg R, Beck BR, Frösner G, Hunt M, Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis A vaccine delayed up to 11 years. Clin Vaccine Immunol. 2011;18(5):885–87. doi:10.1128/CVI.00358-10.
   PubMedGoogle Scholar
• Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol. 2004;72(2):194–96. doi:10.1002/jmv.10574.
   PubMed Web of Science ®Google Scholar
• Chlibek R, von Sonnenburg F, Van Damme P, Smetana J, Tichy P, Gunapalaiah B, Leyssen M, Jacquet J-M. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. J Travel Med. 2011;18(2):145–48. doi:10.1111/j.1708-8305.2010.00499.x.
   PubMed Web of Science ®Google Scholar
• Chen G-J, Sun H-Y, Lin K-Y, Cheng A, Huang Y-C, Hsieh S-M, Sheng W-H, Liu W-C, Hung -C-C, Chang S-C, et al. Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int. 2018;38(7):1198–205. doi:10.1111/liv.13665.
   PubMed Web of Science ®Google Scholar
• de Gouvêa A, de Moraes Pinto MI, Miyamoto M, Machado DM, Duarte Pessoa S and Bononi de Caremo F, Vasconcelos Beltrao S, Menezes Succi RC.. Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure. Revista Paulista De Pediatria (English Edition). 2015;33(2):142–49.
   Google Scholar
• Niewiesk S. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasénas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine. 2003;21(31):4588–92. doi:10.1016/S0264-410X(03)00509-7.
   PubMed Web of Science ®Google Scholar
• Stojanov S, Liese JG, Belohradsky BH, Vandermeulen C, Hoppenbrouwers K, Van der Wielen M, Van Damme P, Georges B, Dupuy M, Scemama M, et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP–IPV–PRP∼T–HBs) combination vaccine. Vaccine. 2007;25(43):7549–58.
   PubMed Web of Science ®Google Scholar
• Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, Lambert SB, Margolis HS. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr. 2004;144(3):327–32.
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A, Kalmanovitch I, Bar-Yochai A, Thoelen S, Safary A, Ashkenazi S. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000;19(11):1045–52. doi:10.1097/00006454-200011000-00004.
   PubMed Web of Science ®Google Scholar
• Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg. 2005;73(2):457–59. doi:10.4269/ajtmh.2005.73.457.
   PubMed Web of Science ®Google Scholar
• Lieberman JM, S-jC C, Partridge S, Hollister JC, Kaplan KM, Jensen EH, Kuter B, Ward JI. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J. 2002;21(4):347–48. doi:10.1097/00006454-200204000-00017.
   PubMed Web of Science ®Google Scholar
• Lagos R, Munoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine. 2003;21(25–26):3730–33. doi:10.1016/S0264-410X(03)00385-2.
   PubMed Web of Science ®Google Scholar
• Kanra G, Yalcin SS, Kara A, Ozmert E, Yurdakök K. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J. 2002;21(8):727–30. doi:10.1097/00006454-200208000-00006.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, Culver D, Bell BP, Margolis HS. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J. 2003;22(4):354–59. doi:10.1097/01.inf.0000059446.52063.b9.
   PubMed Web of Science ®Google Scholar
• Orije MRP, Maertens K, Corbière V, Wanlapakorn N, Van Damme P, Leuridan E, Mascart F. The effect of maternal antibodies on the cellular immune response after infant vaccination: a review. Vaccine. 2020;38(1):20–28. doi:10.1016/j.vaccine.2019.10.025.
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol. 2002;68(4):489–93. doi:10.1002/jmv.10244.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Bülbül M, de Gast GC, van Loon AM, Nalin DR, van Hattum J. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol. 1997;26(2):260–64. doi:10.1016/S0168-8278(97)80039-6.
   PubMed Web of Science ®Google Scholar
• Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24(26):5509–15. doi:10.1016/j.vaccine.2006.04.016.
   PubMed Web of Science ®Google Scholar
• Höhler T, Groeger-Bicanic G, Hoet B, Stoffel M. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine. 2007;25(8):1503–08. doi:10.1016/j.vaccine.2006.10.024.
   PubMed Web of Science ®Google Scholar
• Nelson NP, Murphy TV, McMahon BJ. Hepatitis A vaccination for post-exposure prophylaxis in persons aged 40 years and older. Vaccine. 2014;32(25):2939. doi:10.1016/j.vaccine.2014.01.086.
   PubMed Web of Science ®Google Scholar
• Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine. 1997;15(10):1157–61. doi:10.1016/S0264-410X(96)00310-6.
   PubMed Web of Science ®Google Scholar
• Faridi MMA, Shah N, Ghosh TK, Sankaranarayanan VS, Arankalle V, Aggarwal A, Sathiyasekaran M, Bhattacharya N, Vasanthi T, Chaterjee S, et al. Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study. Indian Pediatr. 2009;46(1):29–34.
   PubMed Web of Science ®Google Scholar
• Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: a review. Hum Vaccin Immunother. 2015;11(11):2582–98. doi:10.1080/21645515.2015.1055424.
   PubMed Web of Science ®Google Scholar
• Lin K-Y, Chen G-J, Lee Y-L, Huang Y-C, Cheng A, Sun H-Y,Chang SY, Liu CE, Hung CC. Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: a review. World J Gastroenterol. 2017;23(20):3589–606.
   PubMed Web of Science ®Google Scholar
• Mor Z, Lurie Y, Katchman E. A case of hepatitis A vaccination failure in an HIV-positive man who had sex with men in Israel. Int J STD AIDS. 2012;23(7):529–30. doi:10.1258/ijsa.2010.010269.
   PubMed Web of Science ®Google Scholar
• Brennan J, Moore K, Sizemore L, Mathieson SA, Wester C, Dunn JR, Schaffner W, Jones TF. Notes from the field: acute hepatitis A virus infection among previously vaccinated persons with HIV infection - Tennessee, 2018. MMWR. 2019;68(14):328–29.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, Ganesan A, Maguire J, Klopfer S, Brandt C, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis. 2011;203(12):1815–23. doi:10.1093/infdis/jir180.
   PubMed Web of Science ®Google Scholar
• Kernéis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E, Pacanowski J, Lortholary O, Abgrall S, Boëlle P-Y, et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr. 2011;57(3):e63–6. doi:10.1097/QAI.0b013e31821fdec3.
   PubMed Web of Science ®Google Scholar
• Jabłonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J STD AIDS. 2014;25(10):745–50. doi:10.1177/0956462413518902.
   PubMed Web of Science ®Google Scholar
• Cheng A, Chang S-Y, Sun H-Y, Tsai M-S, Liu W-C, Su Y-C, Wu P-Y, Hung C-C, Chang S-C. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in human immunodeficiency virus-positive adults on antiretroviral therapy. J Infect Dis. 2017;215(4):606–13.
   PubMed Web of Science ®Google Scholar
• Villarejos VM, Serra J, Anderson-Visona K, Mosley JW. Hepatitis A virus infection in households. Am J Epidemiol. 1982;115(4):577–86. doi:10.1093/oxfordjournals.aje.a113339.
   PubMed Web of Science ®Google Scholar
• Coursaget P, Drucker J, Maupas P, Hibon P, Goudeau A, Bernard D, Sauvage D, Lelord G. Epidemiological and serological study of hepatitis A virus outbreaks in France: a comparison between immunoadherence and radioimmunoassay. J Hyg (Lond). 1981;86(2):155–62. doi:10.1017/S0022172400068868.
   PubMedGoogle Scholar
• Werzberger A, Kuter B, Nalin D. Six years’ follow-up after hepatitis A vaccination. N Engl J Med. 1998;338(16):1160. doi:10.1056/NEJM199804163381615.
   PubMed Web of Science ®Google Scholar
• Yu C, Mayorga O, Emerson SU, Purcell RH, Herzog C. Antibodies to HAV 3C proteinase in naturally infected and vaccine-protected children: 6½-year follow-up data of a placebo-controlled field trial. Poster presented at: 45th ICAAC; 2005 Sep 21–24; New Orleans.
   Google Scholar
• Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 2005;23(44):5144–48. doi:10.1016/j.vaccine.2005.06.017.
   PubMed Web of Science ®Google Scholar
• Espul C, Benedetti L, Cuello H, Houillon G, Rasuli A. Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepat Med. 2012;4:53–60. doi:10.2147/HMER.S33847.
   PubMedGoogle Scholar
• Espul C, Benedetti L, Linares M, Cuello H, Rasuli A. Five-year follow-up of immune response after one or two doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. J Viral Hepat. 2015;22(4):453–58. doi:10.1111/jvh.12317.
   PubMed Web of Science ®Google Scholar
• López EL, Contrini MM, Mistchenko A, Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J. 2010;29:568–70.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang X, Li R, Meng Z, Zhang Y, Gong J, Ma J, Li Y, Zhao Y, Li Y, et al. Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains). Zhonghua Yi Xue Za Zhi. 2002;82(10):678–81.
   PubMedGoogle Scholar
• Böttiger M, Christenson B, Grillner L. Hepatitis A immunity in the Swedish population. A study of the prevalence of markers in the Swedish population. Scand J Infect Dis. 1997;29(2):99–102. doi:10.3109/00365549709035867.
   PubMed Web of Science ®Google Scholar
• Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis. 1995;171(Suppl. 1):S2–8. doi:10.1093/infdis/171.Supplement_1.S2.
   PubMedGoogle Scholar
• Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Byström E, Lopalco P, Alfonsi V, Chilbek R, Dominguez A, et al. Seroprevalence and susceptibility to hepatitis A in the European union and European economic area: a systematic review. Lancet Infect Dis. 2017;17(10):e306–e319. doi:10.1016/S1473-3099(17)30392-4.
   PubMed Web of Science ®Google Scholar
• Gripenberg M, Aloysia D’Cor N, L’Azou M, Marsh G, Druelles S, Nealon J. Changing sero-epidemiology of hepatitis A in Asia Pacific countries: A systematic review. Int J Infect Dis. 2018;68:13–17. doi:10.1016/j.ijid.2017.12.021.
   PubMed Web of Science ®Google Scholar
• Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine. 2000;18(Suppl 1):S57–60. doi:10.1016/S0264-410X(99)00466-1.
   PubMedGoogle Scholar
• Koroglu M, Jacobsen KH, Demiray T, Ozbek A, Erkorkmaz U, Altindis M. Socioeconomic indicators are strong predictors of hepatitis A seroprevalence rates in the Middle East and North Africa. J Infect Public Health. 2017;10(5):513–17. doi:10.1016/j.jiph.2016.09.020.
   PubMed Web of Science ®Google Scholar
• Jacobsen KH. Hepatitis A virus in West Africa: is an epidemiological transition beginning? Niger Med J. 2014;55(4):279–84. doi:10.4103/0300-1652.137185.
   PubMedGoogle Scholar
• Ximenes RAdA, Martelli CMT, Amaku M, Sartori AMC, de Soárez PC, Novaes HMD, Pereira LMMB, Moreira RC, Figueiredo GM, de Azevedo RS, et al. Modelling the force of infection for hepatitis A in an urban population-based survey: a comparison of transmission patterns in Brazilian macro-regions. PLoS ONE. 2014;9(5):e94622. doi:10.1371/journal.pone.0094622.
   PubMed Web of Science ®Google Scholar
• López-Gatell H, García-García L, Echániz-Avilés G, Cruz-Hervert P, Olamendi-Portugal M, Castañeda-Desales D, Sanchez-Alemán MÁ, Romero-Martínez M, DeAntonio R, Cervantes-Apolinar MY, et al. Hepatitis A seroprevalence in adolescents and young adults in Mexico: a 2012 national health and nutrition survey analysis. Vaccine. 2018;36(52):8094–99. doi:10.1016/j.vaccine.2018.10.037.
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996–2004. Vaccine. 2007;25(18):3581–87. doi:10.1016/j.vaccine.2007.01.081.
   PubMed Web of Science ®Google Scholar
• Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, Ropero AM, Shouval D, Ward W, Van Damme P, et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat. 2008;15(Suppl 2):1–15. doi:10.1111/j.1365-2893.2008.01022.x.
   PubMedGoogle Scholar
• Stuurman AL, Marano C, Bunge EM, de Moerlooze L, Shouval D. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review. Hum Vaccin Immunother. 2017;13(3):724–36. doi:10.1080/21645515.2016.1242539.
   PubMed Web of Science ®Google Scholar
• Suwantika AA, Beutels P, Postma MJ. Cost-effectiveness of hepatitis A vaccination in Indonesia. Hum Vaccin Immunother. 2014;10(8):2342–49. doi:10.4161/hv.29353.
   PubMed Web of Science ®Google Scholar
• Cervio G, Trentadue J, D’Agostino D, Luque C, Giorgi M, Armoni J, Debbag R. Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program. Hepat Med. 2011;3:99–106. doi:10.2147/HMER.S22309.
   PubMedGoogle Scholar
• Blanco Fernández MD, Torres C, Riviello-López G, Poma HR, Rajal VB, Nates S, Cisterna DM, Campos RH, Mbayed VA. Analysis of the circulation of hepatitis A virus in Argentina since vaccine introduction. Clin Microbiol Infect. 2012;18(12):E548–51. doi:10.1111/1469-0691.12034.
   PubMed Web of Science ®Google Scholar
• Vizzotti C, Pippo T, Urueña A, Altuna J, Palópoli G, Hernández ML, Artola MF, Fernández H, Orellano P, Cañero-Velasco MC, et al. Economic analysis of the single-dose immunization strategy against hepatitis A in Argentina. Vaccine. 2015;33(Suppl 1):A227–32. doi:10.1016/j.vaccine.2014.12.077.
   PubMedGoogle Scholar
• Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust. 2004;181(9):482–85. doi:10.5694/j.1326-5377.2004.tb06404.x.
   PubMed Web of Science ®Google Scholar
• Thompson C, Dey A, Fearnley E, Polkinghorne B, Beard F. Impact of the national targeted Hepatitis A immunisation program in Australia: 2000–2014. Vaccine. 2017;35(1):170–76. doi:10.1016/j.vaccine.2016.11.002.
   PubMed Web of Science ®Google Scholar
• Fisenka EG, Germanovich FA, Glinskaya IN, Lyabis OI, Rasuli AM. Effectiveness of universal hepatitis A immunization of children in Minsk City, Belarus: four-year follow-up. J Viral Hepat. 2008;15(Suppl 2):57–61. doi:10.1111/j.1365-2893.2008.01031.x.
   PubMedGoogle Scholar
• Souto FJD, de Brito WI, CJF F. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. Vaccine. 2019;37(6):771–75. doi:10.1016/j.vaccine.2018.12.054.
   PubMed Web of Science ®Google Scholar
• Mao JS, Chai SA, Xie RY, Chen NL, Jiang Q, Zhu XZ, Zhang SY, Huang HY, Mao HW, Bao XN, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine. 1997;15(9):944–47. doi:10.1016/S0264-410X(96)00304-0.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhu X, Ding Y, Gao Z, Li Y, Shan A, Liu Y, Xia W. Evaluation on the hepatitis A vaccine in preventing hepatitis A infection in Tianjin, from 2000 to 2011]. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35(10):1127–30.
   PubMedGoogle Scholar
• Wang H, Gao P, Chen W, Bai S, Lv M, Ji W, Pang X, Wu J. Changing epidemiological characteristics of Hepatitis A and warning of Anti-HAV immunity in Beijing, China: a comparison of prevalence from 1990 to 2017. Hum Vaccin Immunother. 2019;15(2):420–25. doi:10.1080/21645515.2018.1529128.
   PubMed Web of Science ®Google Scholar
• Yan B-Y, Lv -J-J, Liu J-Y, Feng Y, Wu W-L, A-Q X, Zhang L. Changes in seroprevalence of hepatitis A after the implementation of universal childhood vaccination in Shandong Province, China: a comparison between 2006 and 2014. Int J Infect Dis. 2019;82:129–34. doi:10.1016/j.ijid.2019.03.005.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang L, Feng D, Zhao S, Liu Q, Xu J, Lu M, Li J, Zhang Y, Guo W, et al. The impact of universal live attenuated hepatitis A vaccines in Henan, China, 2005–2018.  International Journal of Infectious Diseases. 2020;93:163–67. doi:10.1016/j.ijid.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Wang F, Sun X, Wang F, Zheng H, Jia Z, Zhang G, Bi S, Miao N, Zhang S, Cui F, et al. Changing epidemiology of Hepatitis A in China: evidence from three national serological surveys and the national notifiable disease reporting system. Hepatology. (2020);Online ahead of print. doi:10.1002/hep.31429.
   Google Scholar
• Mellou K, Sideroglou T, Papaevangelou V, Katsiaflaka A, Bitsolas N, Verykouki E, Triantafillou E, Baka A, Georgakopoulou T, Hadjichristodoulou C, et al. Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks. PLoS ONE. 2015;10(1):e0116939. doi:10.1371/journal.pone.0116939.
   PubMed Web of Science ®Google Scholar
• Papaevangelou V, Alexopoulou Z, Hadjichristodoulou C, Kourlamba G, Katsioulis A, Theodoridou K, Theodoridou M. Time trends in pediatric hospitalizations for hepatitis A in Greece (1999–2013): assessment of the impact of universal infant immunization in 2008. Hum Vaccin Immunother. 2016;12(7):1852–56.
   PubMed Web of Science ®Google Scholar
• Belmaker I, Dukhan L, Yosef Y, Leventhal A, Dagan R. Elimination of hepatitis A infection outbreaks in day care and school settings in southern Israel after introduction of the national universal toddler hepatitis A immunization program. Pediatr Infect Dis J. 2007;26(1):36–40. doi:10.1097/01.inf.0000247105.45185.13.
   PubMed Web of Science ®Google Scholar
• Barkai G, Belmaker I, Givon-Lavi N, Dagan R. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J. 2009;28(5):391–93. doi:10.1097/INF.0b013e318190655c.
   PubMed Web of Science ®Google Scholar
• Levine H, Kopel E, Anis E, Givon-Lavi N, Dagan R. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Eurosurveillance. 2015;20(7):3–10. doi:10.2807/1560-7917.ES2015.20.7.21040.
   Web of Science ®Google Scholar
• Galor I, Perry Markovich M, Wolf D, Haber M, Hartal M, Avramovich E. Population seroprotection against hepatitis A virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule. Vaccine. 2020;38(7):1593–96. doi:10.1016/j.vaccine.2019.12.041.
   PubMed Web of Science ®Google Scholar
• Chironna M, Prato R, Sallustio A, Martinelli D, Tafuri S, Quarto M, Germinario C. Hepatitis A in Puglia (South Italy) after 10 years of universal vaccination: need for strict monitoring and catch-up vaccination. BMC Infect Dis. 2012;12(1):271. doi:10.1186/1471-2334-12-271.
   PubMedGoogle Scholar
• Gallone MF, Desiante F, Gallone MS, Barbuti G, Tafuri S, Germinario C. Serosurveillance of hepatitis A in a region which adopted the universal mass vaccination. Med (Baltimore). 2017;96(9):e5884. doi:10.1097/MD.0000000000005884.
   PubMed Web of Science ®Google Scholar
• Estripeaut D, Contreras R, Tinajeros O, Castrejón MM, Shafi F, Ortega-Barria E, DeAntonio R. Impact of Hepatitis A vaccination with a two-dose schedule in Panama: results of epidemiological surveillance and time trend analysis. Vaccine. 2015;33(28):3200–07. doi:10.1016/j.vaccine.2015.04.100.
   PubMed Web of Science ®Google Scholar
• Oviedo M, Pilar Muñoz M, Domínguez A, Borras E, Carmona G. A statistical model to estimate the impact of a hepatitis A vaccination programme. Vaccine. 2008;26(48):6157–64. doi:10.1016/j.vaccine.2008.08.066.
   PubMed Web of Science ®Google Scholar
• Martínez A, Broner S, Sala MR, Manzanares-Laya S, Godoy P, Planas C, Minguell S, Torner N, Jané M, Domínguez A, et al. Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program. Hum Vaccin Immunother. 2015;11(1):192–97. doi:10.4161/hv.35861.
   PubMed Web of Science ®Google Scholar
• Romero C, Perdomo V, Chamorro F, Assandri E, Pírez M, Montano A. Prevención de hepatitis A mediante vacunación en Uruguay (2005–2010). Rev Méd Urug. 2012;28:115–22.
   Google Scholar
• Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294(2):194–201. doi:10.1001/jama.294.2.194.
   PubMed Web of Science ®Google Scholar
• Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis. 2008;197(9):1282–88. doi:10.1086/586899.
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hess S, Bulkow LR, Castrodale L, Provo G, McMahon BJ. Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska. Vaccine. 2010;28(38):6298–304. doi:10.1016/j.vaccine.2010.06.113.
   PubMed Web of Science ®Google Scholar
• Erhart LM, Ernst KC. The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988–2007). Vaccine. 2012;30(42):6103–10. doi:10.1016/j.vaccine.2012.07.029.
   PubMed Web of Science ®Google Scholar
• Klevens RM, Denniston MM, Jiles-Chapman RB, Murphy TV. Decreasing immunity to hepatitis A virus infection among US adults: findings from the National Health and Nutrition Examination Survey (NHANES), 1999–2012. Vaccine. 2015;33(46):6192–98. doi:10.1016/j.vaccine.2015.10.009.
   PubMed Web of Science ®Google Scholar
• Collier MG, Tong X, Xu F. Hepatitis A hospitalizations in the United States, 2002–2011. Hepatology. 2015;61(2):481–85. doi:10.1002/hep.27537.
   PubMed Web of Science ®Google Scholar
• Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999–2011: a new concern for adults. J Infect Dis. 2015;212(2):176–82. doi:10.1093/infdis/jiu834.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary; 2019 [accessed 2020 Mar 12]. http://apps.who.int/immunization_monitoring/globalsummary.
   Google Scholar
• Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, state, and selected local area vaccination coverage among children aged 19–35 months - United States, 2013. MMWR. 2014;63:741–48.
   PubMed Web of Science ®Google Scholar
• Dhankhar P, Nwankwo C, Pillsbury M, Lauschke A, Goveia MG, Acosta CJ, Elbasha EH. Public health impact and cost-effectiveness of hepatitis A vaccination in the United States: a disease transmission dynamic modeling approach. Value Health. 2015;18(4):358–67. doi:10.1016/j.jval.2015.02.004.
   PubMed Web of Science ®Google Scholar
• Curran D, de Ridder M, van Effelterre T. The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: is one dose sufficient? Hum Vaccin Immunother. 2016;12(11):2765–71. doi:10.1080/21645515.2016.1203495.
   PubMed Web of Science ®Google Scholar
• Jayasundara D, Hui BB, Regan DG, Heywood AE, MacIntyre CR, Wood JG. Modelling the decline and future of hepatitis A transmission in Australia. J Viral Hepat. 2019;26:199–207.
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics. 2007;119(1):e22–9. doi:10.1542/peds.2006-1572.
   PubMed Web of Science ®Google Scholar
• Cutts FT, Hanson M. Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countries. Trop Med Int Health. 2016;21(9):1086–98. doi:10.1111/tmi.12737.
   PubMed Web of Science ®Google Scholar
• Patterson J, Abdullahi L, Hussey GD, Muloiwa R, Kagina BM. A systematic review of the epidemiology of hepatitis A in Africa. BMC Infect Dis. 2019;19(1):651. doi:10.1186/s12879-019-4235-5.
   PubMed Web of Science ®Google Scholar
• Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine. 2004;22(31–32):4342–50. doi:10.1016/j.vaccine.2004.04.014.
   PubMed Web of Science ®Google Scholar
• Bassal R, Weil M, Cohen D, Sofer D, Mendelson E, Shohat T. Seroprevalence of hepatitis A twelve years after the implementation of Toddlers’ vaccination: a population-based study in Israel. Pediatr Infect Dis J. 2017;36(10):e248–e251. doi:10.1097/INF.0000000000001640.
   PubMed Web of Science ®Google Scholar
• Goodman RA, Foster KL, Trowbridge FL, Figueroa JP. Global disease elimination and eradication as public health strategies. Proceedings of a conference; 1998 Feb 23–25; Atlanta, Georgia, USA. Bull World Health Organ 1998; 76(Suppl 2):5–162.
   Google Scholar
• Van der Meeren O, Crasta P, de Ridder M. A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults. Hum Vaccin Immunother. 2015;11(7):1729–34. doi:10.1080/21645515.2015.1045167.
   PubMed Web of Science ®Google Scholar
• Tjon GMS, Coutinho RA, Van den Hoek A, Esman S, Wijkmans CJ, Hoebe CJPA, Wolters B, Swaan C, Geskus RB, Dukers N, et al. High and persistent excretion of hepatitis A virus in immunocompetent patients. J Med Virol. 2006;78(11):1398–405. doi:10.1002/jmv.20711.
   PubMed Web of Science ®Google Scholar
• Inoue K, Yoshiba M, Yotsuyanagi H, Otsuka T, Sekiyama K, Fujita R. Chronic hepatitis A with persistent viral replication. J Med Virol. 1996;50(4):322–24. doi:10.1002/(SICI)1096-9071(199612)50:4<322::AID-JMV7>3.0.CO;2-A.
   PubMed Web of Science ®Google Scholar
• Biziagos E, Passagot J, Crance JM, Deloince R. Long-term survival of hepatitis A virus and poliovirus type 1 in mineral water. Appl Environ Microbiol. 1988;54(11):2705–10. doi:10.1128/AEM.54.11.2705-2710.1988.
   PubMed Web of Science ®Google Scholar
• Manor Y, Lewis M, Ram D, Daudi N, Mor O, Savion M,Kra-Oz Z, Shemer Avni Y, Sheffer R, Shouval D, et al. Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers’ vaccination since 1999 and low clinical incidence in all age groups. J Infect Dis. 2017;215(4):574–80.
   PubMed Web of Science ®Google Scholar
• Yanez LA, Lucero NS, Barril PA, MDP D, Tenaglia MM, Spinsanti LI, Nates SV, Isa MB, Ré VE. Evidence of hepatitis A virus circulation in central Argentina: seroprevalence and environmental surveillance. J Clin Virol. 2014;59(1):38–43. doi:10.1016/j.jcv.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Ping LH, Lemon SM. Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol. 1992;66(4):2208–16. doi:10.1128/JVI.66.4.2208-2216.1992.
   PubMed Web of Science ®Google Scholar
• Pérez-Sautu U, Costafreda MI, Caylà J, Tortajada C, Lite J, Bosch A, Pintó RM. Hepatitis A virus vaccine escape variants and potential new serotype emergence. Emerging Infect Dis. 2011;17(4):734–37. doi:10.3201/eid1704.101169.
   PubMed Web of Science ®Google Scholar
• Sabrià A, Gregori J, Garcia-Cehic D, Guix S, Pumarola T, Manzanares-Laya S, Caylà JA, Bosch A, Quer J, Pintó RM, et al. Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients: implications for immunization policies. EBioMedicine. 2019;39:348–57. doi:10.1016/j.ebiom.2018.11.023.
   PubMed Web of Science ®Google Scholar
• Trujillo-Ochoa JL, Viera-Segura O, Fierro NA. Challenges in management of hepatitis A virus epidemiological transition in Mexico. Ann Hepatol. 2019;18(1):14–22. doi:10.5604/01.3001.0012.7857.
   PubMed Web of Science ®Google Scholar
• Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011;10(1):57. doi:10.1186/1476-072X-10-57.
   PubMedGoogle Scholar
• Itani T, Jacobsen KH, Nguyen T, Wiktor SZ. A new method for imputing country-level estimates of hepatitis A virus endemicity levels in the Eastern Mediterranean region. Vaccine. 2014;32(46):6067–74. doi:10.1016/j.vaccine.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Arankalle V, Tiraki D, Kulkarni R, Palkar S, Malshe N, Lalwani S,  Mishra A. Age-stratified anti-HAV positivity in Pune, India after two decades: has voluntary vaccination impacted overall exposure to HAV? J Viral Hepat. 2019;26(6):757–60.
   PubMed Web of Science ®Google Scholar
• Jayasundara D, Hui BB, Regan DG, Heywood AE, MacIntyre CR, Wood JG. Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia. Vaccine. 2017;35:5228–34.
   PubMed Web of Science ®Google Scholar
• Kabrane-Lazizi Y, Emerson SU, Herzog C, Purcell RH. Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children. Vaccine. 2001;19(20–22):2878–83. doi:10.1016/S0264-410X(00)00560-0.
   PubMed Web of Science ®Google Scholar
• Su Q, Guo M, Jia Z, Qiu F, Lu X, Gao Y, Meng Q, Tian R, Bi S, Yi Y, et al. Epitope-based recombinant diagnostic antigen to distinguish natural infection from vaccination with hepatitis A virus vaccines. J Virol Methods. 2016;233:41–45. doi:10.1016/j.jviromet.2016.02.014.
   PubMed Web of Science ®Google Scholar
• Ye C, Luo J, Wang X, Xi J, Pan Y, Chen J, Yang X, Li G, Sun Q, Yang J, et al. Development of a peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in a phase IV study. Eur J Clin Microbiol Infect Dis. 2017;36(11):2165–70. doi:10.1007/s10096-017-3040-6.
   PubMed Web of Science ®Google Scholar
• Bohm K, Filomena A, Schneiderhan-Marra N, Krause G, Sievers C. Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. Vaccine. 2017;35:5883–89.
   PubMed Web of Science ®Google Scholar
• Herzog C, Mayorga O. Serologic differential diagnosis of hepatitis A virus (HAV) infected and vaccinated individuals: how long persist antibodies to non-structural HAV proteins? Vaccine. 2018;36(27):3883–84. doi:10.1016/j.vaccine.2018.05.015.
   PubMed Web of Science ®Google Scholar
• Werber D, Michaelis K, Hausner M, Sissolak D, Wenzel J, Bitzegeio J, Belting A, Sagebiel D, Faber M. Ongoing outbreaks of hepatitis A among men who have sex with men (MSM), Berlin, November 2016 to January 2017 - linked to other German cities and European countries. Eurosurveillance. 2017; 22(5):pii=30457
   Web of Science ®Google Scholar
• Mariojoules J, Castro G, Pisano MB, Barbero P, Fantilli A, Borda M, Canna F, Barbás G, Ré V. Hepatitis A outbreak affecting men who have sex with men (MSM) in central Argentina, occurred in July 2017–April 2018, later than the European outbreak. J Clin Virol. 2019;117:49–53. doi:10.1016/j.jcv.2019.05.014.
   PubMed Web of Science ®Google Scholar
• Foster MA, Hofmeister MG, Kupronis BA, Lin Y, Xia G-L, Yin S, Teshale E. Increase in hepatitis A virus infections - United States, 2013–2018. MMWR. 2019;68(18):413–15.
   PubMed Web of Science ®Google Scholar
• Alberts CJ, Boyd A, Bruisten SM, Heijman T, Hogewoning A, van Rooijen M, Siedenburg E, Sonder GJB. Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands. Vaccine. 2019;37(21):2849–56. doi:10.1016/j.vaccine.2019.03.048.
   PubMed Web of Science ®Google Scholar
• Hu X, Collier MG, Xu F. Hepatitis A Outbreaks in Developed Countries: detection, Control, and Prevention. Foodborne Pathog Dis. 2020;17(3):166–71. doi:10.1089/fpd.2019.2648.
   PubMed Web of Science ®Google Scholar
• Severi E, Verhoef L, Thornton L, Guzman-Herrador BR, Faber M, Sundqvist L, Rimhanen-Finne R, Roque-Afonso AM, Ngui SL, Allerberger F, et al. Large and prolonged food-borne multistate hepatitis A outbreak in Europe associated with consumption of frozen berries, 2013 to 2014. Eurosurveillance. 2015;20(29):pii=21192. doi:10.2807/1560-7917.ES2015.20.29.21192.
   Web of Science ®Google Scholar
• Enkirch T, Severi E, Vennema H, Thornton L, Dean J, M-L B, Ciccaglione AR, Bruni R, Christova I, Ngui SL, et al. Improving preparedness to respond to cross-border hepatitis A outbreaks in the European union/European economic area: towards comparable sequencing of hepatitis A virus. Euro Surveill. 2019;24(28). doi:10.2807/1560-7917.ES.2019.24.28.1800397.
   Google Scholar
• Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months - United States, 2017. MMWR. 2018;67:1123–28.
   PubMed Web of Science ®Google Scholar
• Foster M, Ramachandran S, Myatt K, Donovan D, Bohm S, Fiedler J,Barbeau B, Collins J, Thoroughman D, McDonald E, et al. Hepatitis A virus outbreaks associated with drug use and homelessness — California, Kentucky, Michigan, and Utah, 2017. MMWR. 2018;67(43):1208–10.
   PubMed Web of Science ®Google Scholar
• Yin S, Barker L, Ly KN, Kilmer G, Foster MA, Drobeniuc J, Jiles RB. Susceptibility to hepatitis A virus infection in the United States, 2007–2016. Clin Infect Dis. 2020;14:38.
   Google Scholar
• Tavoschi L, Severi E, Carrillo Santisteve P, Lopalco P. HepatitisA in the EU/EEA: the case for scaling up prevention. Vaccine. 2018;36:2501–03.
   PubMed Web of Science ®Google Scholar